Marker Therapeutics, Inc. (MRKR) stock
MRKRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.87−0.03 (-3.33%)
Close on Nov 13, 2026Market cap $14.51MP/E –Yield –
Marker Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Marker Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $8.81M, down 44.5% year over year. For fiscal 2025 it was $11.80M, down 12.4% from the year before. Over ten years it grew 21.3% a year on average. The highest annual figure on record is $27.79M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.80M | -12.4% |
| FY2024 | Dec 31, 2024 | $13.47M | +29.3% |
| FY2023 | Dec 31, 2023 | $10.42M | -13.0% |
| FY2022 | Dec 31, 2022 | $11.97M | -56.9% |
| FY2021 | Dec 31, 2021 | $27.79M | +47.2% |
| FY2020 | Dec 31, 2020 | $18.88M | +47.9% |
| FY2019 | Dec 31, 2019 | $12.76M | +60.5% |
| FY2018 | Dec 31, 2018 | $7.95M | +51.5% |
| FY2017 | Dec 31, 2017 | $5.25M | +38.2% |
| FY2016 | Dec 31, 2016 | $3.80M | +122.1% |
| FY2015 | Dec 31, 2015 | $1.71M | +805.4% |
| FY2014 | Dec 31, 2014 | $189.00K | -72.9% |
| FY2013 | Dec 31, 2013 | $697.63K | -34.0% |
| FY2012 | Dec 31, 2012 | $1.06M | +419.0% |
| FY2011 | Dec 31, 2011 | $203.73K | -29.8% |
| FY2010 | Dec 31, 2010 | $290.05K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.48M | -64.7% |
| Q1 FY2026 | Mar 31, 2026 | $2.84M | -9.3% |
| Q4 FY2025 | Dec 31, 2025 | $2.14M | -57.9% |
| Q3 FY2025 | Sep 30, 2025 | $2.35M | -32.4% |
| Q2 FY2025 | Jun 30, 2025 | $4.18M | +78.9% |
| Q1 FY2025 | Mar 31, 2025 | $3.14M | +21.8% |
| Q4 FY2024 | Dec 31, 2024 | $5.09M | +94.3% |
| Q3 FY2024 | Sep 30, 2024 | $3.47M | +69.7% |
| Q2 FY2024 | Jun 30, 2024 | $2.34M | -1.8% |
| Q1 FY2024 | Mar 31, 2024 | $2.58M | -23.7% |
| Q4 FY2023 | Dec 31, 2023 | $2.62M | +19.9% |
| Q3 FY2023 | Sep 30, 2023 | $2.04M | -43.1% |
| Q2 FY2023 | Jun 30, 2023 | $2.38M | -18.7% |
| Q1 FY2023 | Mar 31, 2023 | $3.38M | -51.9% |
| Q4 FY2022 | Dec 31, 2022 | $2.18M | -72.8% |
| Q3 FY2022 | Sep 30, 2022 | $3.59M | -47.1% |
| Q2 FY2022 | Jun 30, 2022 | $2.92M | -60.2% |
| Q1 FY2022 | Mar 31, 2022 | $7.03M | +24.5% |
| Q4 FY2021 | Dec 31, 2021 | $8.02M | +34.0% |
| Q3 FY2021 | Sep 30, 2021 | $6.78M | +41.2% |
| Q2 FY2021 | Jun 30, 2021 | $7.35M | +71.8% |
| Q1 FY2021 | Mar 31, 2021 | $5.64M | +47.9% |
| Q4 FY2020 | Dec 31, 2020 | $5.98M | +63.4% |
| Q3 FY2020 | Sep 30, 2020 | $4.80M | +54.0% |
| Q2 FY2020 | Jun 30, 2020 | $4.28M | +35.7% |
| Q1 FY2020 | Mar 31, 2020 | $3.82M | +34.7% |
| Q4 FY2019 | Dec 31, 2019 | $3.66M | +100.4% |
| Q3 FY2019 | Sep 30, 2019 | $3.12M | +95.0% |
| Q2 FY2019 | Jun 30, 2019 | $3.15M | +119.6% |
| Q1 FY2019 | Mar 31, 2019 | $2.83M | +74.5% |
| Q2 FY2018 | Jun 30, 2018 | $1.83M | +51.9% |
| Q1 FY2018 | Mar 31, 2018 | $1.60M | +61.7% |
| Q4 FY2017 | Dec 31, 2017 | $1.44M | +214.3% |
| Q3 FY2017 | Sep 30, 2017 | $1.62M | +46.3% |
| Q2 FY2017 | Jun 30, 2017 | $1.20M | -3.6% |
| Q1 FY2017 | Mar 31, 2017 | $989.09K | – |
| Q4 FY2016 | Dec 31, 2016 | $456.79K | – |
| Q3 FY2016 | Sep 30, 2016 | $1.11M | – |
| Q2 FY2016 | Jun 30, 2016 | $1.25M | – |
See a number that looks wrong?